Vanguard Total Stock Market Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Total Stock Market Index Fund ETF trades at $381.95, while State Street SPDR S&P Biotech ETF trades at $159.35. Which is the better fit depends on your goals.
| VTI | XBI | |
|---|---|---|
52-Week High | $381.78 | $164.28 |
52-Week Low | $311.68 | $86.92 |
Sector | — | Broad Market / Factor |
Signals from Pluang's Aura AI — not financial advice
VTI trades at $381.83, up 0.05% with a bullish technical signal from moving averages and strong institutional inflows. The ETF's 0.03% expense ratio and over 3,500 holdings provide broad U.S. equity exposure. Recent dividend of $1.04 was declared for June 2026.
Outlook remains positive due to low-cost diversification and steady institutional demand. Risks include market volatility and concentration in large-cap tech. Long-term growth potential is supported by historical performance but requires monitoring of economic conditions.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Trailing returns across standard periods
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →